Versant Ventures

Granite Bio is a biotechnology company that specializes in the development of novel monoclonal antibodies aimed at treating inflammatory, autoimmune, and fibrotic disorders. The company's primary focus is on creating therapeutic antibodies that deplete pathogenic cells and selectively target key biological pathways associated with these diseases. By advancing innovative antibody treatments, Granite Bio aims to contribute significantly to the fields of biotechnology and pharmaceuticals, addressing critical needs in the life sciences sector.

Helicore Biopharma is a biopharmaceutical company dedicated to developing innovative treatments for obesity and related metabolic disorders. Its portfolio includes novel therapeutics based on glucose-dependent insulinotropic peptide (GIP) antagonism and monoclonal antibodies that bind circulating GIP ligands, forming a modular platform for anti-obesity medicines. The company aims to help patients with obesity and related conditions achieve significant weight loss.

Light Horse Therapeutics is a biotechnology company specializing in the application of gene editing to small-molecule drug discovery. It develops innovative methods to target the root causes of severe and life-threatening diseases, with an initial focus on challenging oncology targets. The company's advanced platform identifies critical functional domains within disease-related proteins, enabling the development of more effective therapies.

858 Therapeutics is a biotechnology company dedicated to the discovery of small molecule therapeutics aimed at treating cancers and other diseases, particularly those resistant to existing therapies. The company employs innovative strategies in areas such as synthetic lethality, innate immunity, and RNA modulation to develop its therapeutic candidates. Its lead program focuses on a PARG inhibitor, which is currently in early clinical development. By leveraging its platform to investigate the role of RNA modifying proteins in disease biology, 858 Therapeutics is generating a pipeline of targeted small molecules that address critical unmet medical needs in oncology and immunology.

Borealis Biosciences is a discovery-stage biotechnology company focused on developing next-generation RNA-based therapies, particularly targeting kidney diseases. The company specializes in molecular and cellular biology, chemistry, and analytical capabilities, utilizing these strengths to identify and map target opportunities within specific patient subsets affected by kidney conditions. Borealis aims to enhance the delivery mechanisms of RNA medicines to distinct cell types, thereby addressing significant unmet medical needs in the treatment of kidney diseases.

Jade Biosciences is a biopharmaceutical company dedicated to developing innovative therapies for unmet needs in autoimmune diseases. Its lead asset, JADE-001, targets the APRIL pathway for treating IgA nephropathy, with initial clinical trials planned. Additionally, Jade has two preclinical antibody discovery programs, JADE-002 and JADE-003. The company was founded upon assets licensed from Paragon Therapeutics.

Bright Peak Therapeutics is a biotechnology company focused on developing a range of immunotherapies aimed at treating cancer and autoimmune diseases. The company specializes in creating immuno-cytokines that possess pharmacological properties enabling tissue and cell-specific targeting of cytokine payloads. This innovative approach is designed to enhance the efficacy of treatments, ultimately improving patient outcomes and quality of life. By leveraging its expertise in cytokine therapeutics, Bright Peak aims to advance the field of immunotherapy and provide effective solutions for challenging medical conditions.

FireFly Bio is a biotechnology company focused on developing innovative therapies for cancer through its proprietary platform centered on Degrader Antibody Conjugates (DACs). This technology merges the advantages of traditional antibody-drug conjugates (ADCs) with selective protein degradation, allowing for the targeted delivery of therapeutic agents to specific tissues. By leveraging advanced bioconjugate technologies, FireFly Bio aims to create highly specific and effective treatments that enhance patient outcomes. The company's approach emphasizes precision in medicine, seeking to improve the potency and efficacy of cancer therapies.

Enterprise Therapeutics Ltd. is a drug discovery company based in Brighton, United Kingdom, established in 2014. The company is dedicated to researching and developing innovative therapies for respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its focus is on creating disease-modifying treatments that address the underlying mechanisms of mucus congestion in the lungs, which can lead to breathing difficulties and increase the risk of lung infections. By targeting these mechanisms, Enterprise Therapeutics aims to improve the quality of life for patients suffering from these debilitating conditions.

Nexo Therapeutics is a small molecule oncology company focused on discovering and developing innovative drugs for cancer patients who have limited therapeutic options. The company utilizes a unique platform that integrates covalent ligand discovery and chemical biology, allowing it to advance small-molecule therapies aimed at challenging and previously intractable cancer targets. By unlocking a pipeline of novel oncology treatments, Nexo Therapeutics seeks to provide medical professionals with new and effective options to improve patient outcomes in the fight against cancer.

Abdera Therapeutics is an oncology company focused on developing targeted alpha therapies (TATs) for patients suffering from relapsed, refractory, and metastatic cancers. The company employs a precision oncology platform that utilizes purpose-built vectors to deliver high-energy radio-isotopes directly to tumors and metastatic lesions. This innovative approach to targeted radiotherapy aims to improve treatment efficacy for patients with challenging cancer diagnoses. Abdera's work in this emerging field aligns with a significant market potential, as targeted alpha therapies are expected to play a major role in the future of nuclear medicine.

Abdera Therapeutics is an oncology company focused on developing targeted alpha therapies (TATs) for patients suffering from relapsed, refractory, and metastatic cancers. The company employs a precision oncology platform that utilizes purpose-built vectors to deliver high-energy radio-isotopes directly to tumors and metastatic lesions. This innovative approach to targeted radiotherapy aims to improve treatment efficacy for patients with challenging cancer diagnoses. Abdera's work in this emerging field aligns with a significant market potential, as targeted alpha therapies are expected to play a major role in the future of nuclear medicine.

Belharra Therapeutics is a privately held drug discovery company based in the San Francisco Bay Area, with its primary laboratory and offices located in San Diego. The company is focused on developing transformative small molecule drugs to address serious diseases using its innovative photoaffinity-based chemoproteomics platform. This cutting-edge technology allows Belharra scientists to identify small molecule drug candidates that can target any binding site on any protein, regardless of its conformational state or cell type. By integrating advanced biology, medicinal chemistry, and bioinformatics with drug discovery and chemoproteomics screening, Belharra aims to deliver first-in-class medicines that have the potential to significantly improve patient outcomes.

Launchpad Therapeutics is a precision oncology company focused on developing innovative antibody-based treatments for cancer. The company specializes in creating mutant-selective antibodies designed to target specific mutations found in cancer cells. By leveraging artificial intelligence-driven programs, Launchpad Therapeutics aims to deliver novel monoclonal antibodies that offer new avenues for cancer treatment. These efforts are directed towards providing medical professionals with alternative and effective therapeutic options for patients.

iECURE is a biotechnology company dedicated to developing innovative gene editing therapies aimed at treating rare and life-threatening liver disorders, particularly in children. Its approach employs mutation-agnostic in vivo gene insertion techniques, which allow for targeted interventions in diseases characterized by metabolic "loss of function" disorders. By focusing on conditions with high unmet medical needs, iECURE aims to offer potential cures for devastating illnesses that currently lack effective treatment options. The company's commitment to advancing gene editing technology positions it as a key player in the field of genetic medicine.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

Tempest Therapeutics Inc. is a biotechnology company based in South San Francisco, California, focused on developing small molecule therapeutics for cancer treatment. Established in 2011, the company aims to enhance anti-tumor immunity through its innovative drug pipeline, which includes clinical-stage candidates such as TPST-8844, TPST-1120, and TPST-1495. TPST-8844 targets an enzyme that helps tumor cells evade immune responses, while TPST-1120 blocks the PPAR-alpha pathway to stimulate immune effector cells essential for fighting tumors. Additionally, the company's therapeutics address pathways that directly kill tumor cells and activate tumor-specific immunity, positioning Tempest Therapeutics at the forefront of cancer treatment innovation.

Ventus Therapeutics is a biopharmaceutical company focused on discovering and developing innovative small molecule medicines that target the innate immune system. The company employs a structural immunology platform that provides deep insights into molecular structures and mechanisms, enabling precise targeting of the innate immune system. Ventus combines advanced protein engineering capabilities with cutting-edge rational and structure-based drug design tools to create therapeutics aimed at treating autoimmune diseases, inflammatory conditions, and cancer. The company is actively building a diverse pipeline of drug programs that address significant targets within the innate immune system, with the goal of advancing treatments for both acute and chronic inflammatory and immune-related diseases.

Nested Therapeutics is a stealth biotechnology company based in Cambridge, Massachusetts, founded in 2021. The company specializes in the development of precision oncology therapies aimed at targeting specific cancer genes. By identifying new driver mutations, Nested Therapeutics employs a platform that integrates insights from genomics, computational chemistry, proteomics, and artificial intelligence to discover novel small-molecule drugs. This innovative approach enables healthcare professionals to administer more effective precision medications, ultimately improving treatment outcomes for cancer patients.

Coda Biotherapeutics, Inc. is a biotechnology company focused on developing innovative therapies to modulate neuronal activity through its chemogenetic platform. Established in 2014 and based in San Francisco, the company employs gene therapy techniques to modify specific neuronal populations, enabling them to express engineered ligand-gated ion channels that are responsive to a proprietary small molecule. This interaction allows for precise, dose-dependent control of neuronal activity, facilitating the treatment of conditions such as neuropathic pain, epilepsy, and movement disorders. Coda's approach utilizes viral vectors to deliver these engineered neurotransmitter receptors directly to targeted neurons, enhancing the efficiency of treatment for severe nervous system disorders compared to traditional therapies.

858 Therapeutics is a biotechnology company dedicated to the discovery of small molecule therapeutics aimed at treating cancers and other diseases, particularly those resistant to existing therapies. The company employs innovative strategies in areas such as synthetic lethality, innate immunity, and RNA modulation to develop its therapeutic candidates. Its lead program focuses on a PARG inhibitor, which is currently in early clinical development. By leveraging its platform to investigate the role of RNA modifying proteins in disease biology, 858 Therapeutics is generating a pipeline of targeted small molecules that address critical unmet medical needs in oncology and immunology.

Lycia Therapeutics operates as a biotechnology company focused on discovering and developing first-in-class therapeutics using its proprietary Lysosomal Targeting Chimeras (LYTACs) platform. This platform enables the degradation of extracellular and membrane-bound proteins associated with challenging-to-treat diseases like cancer and autoimmune disorders, aiming to provide effective treatments for patients.

iECURE is a biotechnology company dedicated to developing innovative gene editing therapies aimed at treating rare and life-threatening liver disorders, particularly in children. Its approach employs mutation-agnostic in vivo gene insertion techniques, which allow for targeted interventions in diseases characterized by metabolic "loss of function" disorders. By focusing on conditions with high unmet medical needs, iECURE aims to offer potential cures for devastating illnesses that currently lack effective treatment options. The company's commitment to advancing gene editing technology positions it as a key player in the field of genetic medicine.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

T-knife is a biotechnology company focused on developing T cell receptor therapies aimed at treating cancer. Utilizing a humanized T cell receptor (TCR) mice platform, the company is capable of carrying human TCRαβ gene loci and recombining a diverse array of human TCRs. This innovative approach facilitates the efficient generation and virtual selection of T cell receptors tailored for specific human tumor antigens, enhancing the potential for effective cancer therapies. Through its advanced technology, T-knife aims to improve treatment options for patients battling cancer.

Turnstone Biologics Inc. is a clinical-stage biotechnology company based in Ottawa, Canada, with an additional office in New York. Founded in 2015, the company is dedicated to advancing innovative viral immunotherapies aimed at improving cancer patient survival. Its lead product, RIVAL-01, utilizes a vaccinia virus backbone that encodes several immunomodulators, including Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine, which work together to enhance immune activity and optimize the tumor microenvironment for effective cancer treatment. Additionally, Turnstone Biologics is developing next-generation tumor-infiltrating lymphocyte (TIL) therapies by isolating and expanding the most potent and tumor-reactive T cells from patients' tumors, thereby harnessing the body's own immune system to combat solid tumors. Through these innovative approaches, Turnstone Biologics aims to deliver breakthrough cancer immunotherapies that significantly improve clinical outcomes for patients.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

Bright Peak Therapeutics is a biotechnology company focused on developing a range of immunotherapies aimed at treating cancer and autoimmune diseases. The company specializes in creating immuno-cytokines that possess pharmacological properties enabling tissue and cell-specific targeting of cytokine payloads. This innovative approach is designed to enhance the efficacy of treatments, ultimately improving patient outcomes and quality of life. By leveraging its expertise in cytokine therapeutics, Bright Peak aims to advance the field of immunotherapy and provide effective solutions for challenging medical conditions.

Ventus Therapeutics is a biopharmaceutical company focused on discovering and developing innovative small molecule medicines that target the innate immune system. The company employs a structural immunology platform that provides deep insights into molecular structures and mechanisms, enabling precise targeting of the innate immune system. Ventus combines advanced protein engineering capabilities with cutting-edge rational and structure-based drug design tools to create therapeutics aimed at treating autoimmune diseases, inflammatory conditions, and cancer. The company is actively building a diverse pipeline of drug programs that address significant targets within the innate immune system, with the goal of advancing treatments for both acute and chronic inflammatory and immune-related diseases.

Graphite Bio, Inc. is a clinical-stage gene editing company based in South San Francisco, California, that focuses on targeted DNA integration to address severe genetic diseases. The firm employs advanced technology to enable the precise insertion of genetic sequences, effectively correcting mutations, replacing malfunctioning genes, and introducing therapeutic genetic materials into specific regions of the genome. By harnessing high-efficiency targeted gene integration, Graphite Bio aims to develop novel therapies that could potentially cure a wide array of serious and life-threatening conditions. Formerly known as Integral Medicines, Inc., the company rebranded in August 2020 and has operated since its incorporation in 2019. Graphite Bio is committed to the pioneering of a precision gene editing approach designed to fulfill the medical challenge of accurately "finding and replacing" genes.

Monte Rosa Therapeutics is a biotechnology company dedicated to developing innovative cancer therapeutics through the modulation of protein degradation pathways. Specializing in molecular glue degraders (MGDs), the company utilizes the body's natural mechanisms for protein destruction to selectively degrade proteins that are relevant to therapeutic outcomes. Employing its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, Monte Rosa identifies target proteins for degradation by MGDs from its extensive library of over 50,000 molecules. The company's most advanced product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for the treatment of MYC-driven tumors. Monte Rosa Therapeutics aims to deliver pioneering therapies for cancer and potentially other diseases through its innovative approaches.

Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) to treat hematologic and solid malignancies. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company utilizes a specialized platform that integrates gene editing and protein engineering to create allogeneic therapies. This platform allows for the generation of master cell banks of modified immune effector cells, specifically engineered to optimize performance and reduce the risk of rejection by the host immune system. By employing advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to address significant unmet medical needs in cancer and other diseases.

Pipeline Therapeutics Inc. is a biotechnology company based in San Diego, California, specializing in the development and commercialization of small molecules aimed at neuroregeneration. Founded in 2017, the company focuses on promoting functional recovery for various neurological disorders. Its lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor designed to treat mild-to-moderate sensorineural hearing loss associated with cochlear synaptopathy. Additionally, Pipeline Therapeutics has a portfolio of earlier-stage programs, including PIPE-307, which targets remyelination and axonal repair to address conditions like multiple sclerosis. By harnessing the natural repair processes of different nervous system cell types, the company seeks to provide innovative treatments that repair damage within the nervous system.

Gritstone bio is a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surface of infected cells. Gritstone bio's approach leverages the body's natural immune system recognition of targets on abnormal cells, which is applicable to both anti-tumor and anti-viral immunity. Their pipeline includes several product candidates for treating solid tumors, such as GRANITE, SLATE, and CORAL. The company operates in a field that has seen significant advancements with the development and commercialization of immunotherapy drugs like checkpoint inhibitors, transforming cancer treatment.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

RayzeBio, Inc. is a biotechnology company based in San Diego, California, founded in 2020. The company specializes in developing tumor-targeted small molecule medicines that leverage radioisotopes to improve cancer treatment outcomes. RayzeBio focuses on creating innovative radiopharmaceuticals, particularly utilizing alpha-emitting radioisotopes like Actinium-225, to target solid tumors effectively. With a robust pipeline of drug candidates, RayzeBio is committed to addressing significant market opportunities in oncology through late-stage clinical programs, development initiatives, and discovery efforts. The company's mission is to provide effective therapeutic solutions aimed at defeating cancer.

Monte Rosa Therapeutics is a biotechnology company dedicated to developing innovative cancer therapeutics through the modulation of protein degradation pathways. Specializing in molecular glue degraders (MGDs), the company utilizes the body's natural mechanisms for protein destruction to selectively degrade proteins that are relevant to therapeutic outcomes. Employing its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, Monte Rosa identifies target proteins for degradation by MGDs from its extensive library of over 50,000 molecules. The company's most advanced product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for the treatment of MYC-driven tumors. Monte Rosa Therapeutics aims to deliver pioneering therapies for cancer and potentially other diseases through its innovative approaches.

Lava Therapeutics B.V. is a biotechnology company based in Utrecht, the Netherlands, focused on innovative cancer treatments. Founded in 2016, it specializes in the development of proprietary bispecific antibodies that engage gamma-delta T cells, aiming to harness the immune system's power to target and destroy tumor cells. The company's platform creates next-generation γδ T cell engaging antibodies designed for both hematological and solid tumors, emphasizing safety, potency, and cost-effectiveness in its biopharmaceuticals. By combining immune recruiting and activating functionalities, Lava Therapeutics seeks to transform cancer therapy and improve patient outcomes.

Graphite Bio, Inc. is a clinical-stage gene editing company based in South San Francisco, California, that focuses on targeted DNA integration to address severe genetic diseases. The firm employs advanced technology to enable the precise insertion of genetic sequences, effectively correcting mutations, replacing malfunctioning genes, and introducing therapeutic genetic materials into specific regions of the genome. By harnessing high-efficiency targeted gene integration, Graphite Bio aims to develop novel therapies that could potentially cure a wide array of serious and life-threatening conditions. Formerly known as Integral Medicines, Inc., the company rebranded in August 2020 and has operated since its incorporation in 2019. Graphite Bio is committed to the pioneering of a precision gene editing approach designed to fulfill the medical challenge of accurately "finding and replacing" genes.

Chinook Therapeutics, Inc. is a clinical-stage biotechnology company based in Seattle, Washington, that specializes in the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead program is atrasentan, an investigational endothelin receptor antagonist currently prepared for Phase III trials targeting IgA nephropathy and other primary glomerular diseases. In addition to atrasentan, Chinook is developing BION-1301, an investigational anti-APRIL monoclonal antibody evaluated in a Phase Ib trial for IgA nephropathy, and CHK-336, a preclinical candidate aimed at treating an undisclosed ultra-orphan kidney disease. Chinook Therapeutics is also engaged in research programs addressing other rare and severe chronic kidney conditions, including polycystic kidney disease.

T-knife is a biotechnology company focused on developing T cell receptor therapies aimed at treating cancer. Utilizing a humanized T cell receptor (TCR) mice platform, the company is capable of carrying human TCRαβ gene loci and recombining a diverse array of human TCRs. This innovative approach facilitates the efficient generation and virtual selection of T cell receptors tailored for specific human tumor antigens, enhancing the potential for effective cancer therapies. Through its advanced technology, T-knife aims to improve treatment options for patients battling cancer.

Bright Peak Therapeutics is a biotechnology company focused on developing a range of immunotherapies aimed at treating cancer and autoimmune diseases. The company specializes in creating immuno-cytokines that possess pharmacological properties enabling tissue and cell-specific targeting of cytokine payloads. This innovative approach is designed to enhance the efficacy of treatments, ultimately improving patient outcomes and quality of life. By leveraging its expertise in cytokine therapeutics, Bright Peak aims to advance the field of immunotherapy and provide effective solutions for challenging medical conditions.

Monte Rosa Therapeutics is a biotechnology company dedicated to developing innovative cancer therapeutics through the modulation of protein degradation pathways. Specializing in molecular glue degraders (MGDs), the company utilizes the body's natural mechanisms for protein destruction to selectively degrade proteins that are relevant to therapeutic outcomes. Employing its QuEEN platform, which integrates artificial intelligence and proprietary experimental tools, Monte Rosa identifies target proteins for degradation by MGDs from its extensive library of over 50,000 molecules. The company's most advanced product candidate, MRT-2359, specifically targets the translation termination factor protein GSPT1, showing promise for the treatment of MYC-driven tumors. Monte Rosa Therapeutics aims to deliver pioneering therapies for cancer and potentially other diseases through its innovative approaches.

Ventus Therapeutics is a biopharmaceutical company focused on discovering and developing innovative small molecule medicines that target the innate immune system. The company employs a structural immunology platform that provides deep insights into molecular structures and mechanisms, enabling precise targeting of the innate immune system. Ventus combines advanced protein engineering capabilities with cutting-edge rational and structure-based drug design tools to create therapeutics aimed at treating autoimmune diseases, inflammatory conditions, and cancer. The company is actively building a diverse pipeline of drug programs that address significant targets within the innate immune system, with the goal of advancing treatments for both acute and chronic inflammatory and immune-related diseases.

Pandion Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on developing innovative therapeutics for patients with autoimmune diseases. The company’s lead product candidate, PT101, is an engineered interleukin-2 variant currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions, including moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to provide tissue-selective immunomodulation by targeting specific adhesion molecules in the gastrointestinal tract. Pandion employs a network-based approach to immune system conceptualization through its TALON drug design platform and collaborates with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. The company aims to create a new generation of therapeutics that offer enhanced efficacy and safety for the treatment of autoimmune and inflammatory diseases.

Lycia Therapeutics operates as a biotechnology company focused on discovering and developing first-in-class therapeutics using its proprietary Lysosomal Targeting Chimeras (LYTACs) platform. This platform enables the degradation of extracellular and membrane-bound proteins associated with challenging-to-treat diseases like cancer and autoimmune disorders, aiming to provide effective treatments for patients.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 and based in South San Francisco, California. The company is dedicated to developing innovative therapeutics to meet unmet medical needs in viral and liver diseases. Its primary focus is on chronic hepatitis B (CHB), with a robust pipeline that includes several drug candidates: ALG-010133, a synthetic oligonucleotide currently in Phase I clinical trials; ALG-000184, a capsid assembly modulator; ALG-020572, another oligonucleotide; and ALG-125097, an siRNA drug candidate. Additionally, Aligos is advancing ALG-055009, a small molecule THR-ß agonist aimed at treating non-alcoholic steatohepatitis (NASH). Aligos aims to leverage its expertise in liver diseases and viral infections to develop targeted antiviral therapies and establish itself as a leader in this therapeutic area.

VectivBio AG is a clinical-stage biotechnology company based in Basel, Switzerland, founded in 2019 as a spinout from Therachon. The company specializes in the discovery, development, and commercialization of innovative treatments for severe rare diseases, particularly those with significant unmet medical needs. Its lead product candidate, Apraglutide, is a synthetic GLP-2 analog designed to enhance the intestine’s ability to absorb fluids and nutrients, thereby reducing the reliance on parenteral support in patients with short bowel syndrome. VectivBio is dedicated to developing best-in-disease therapies that aim to meaningfully improve the lives of patients and their families, providing more than just incremental advancements over existing standard-of-care options.

Pipeline Therapeutics Inc. is a biotechnology company based in San Diego, California, specializing in the development and commercialization of small molecules aimed at neuroregeneration. Founded in 2017, the company focuses on promoting functional recovery for various neurological disorders. Its lead product candidate, PIPE-505, is a small molecule gamma secretase inhibitor designed to treat mild-to-moderate sensorineural hearing loss associated with cochlear synaptopathy. Additionally, Pipeline Therapeutics has a portfolio of earlier-stage programs, including PIPE-307, which targets remyelination and axonal repair to address conditions like multiple sclerosis. By harnessing the natural repair processes of different nervous system cell types, the company seeks to provide innovative treatments that repair damage within the nervous system.

Coda Biotherapeutics, Inc. is a biotechnology company focused on developing innovative therapies to modulate neuronal activity through its chemogenetic platform. Established in 2014 and based in San Francisco, the company employs gene therapy techniques to modify specific neuronal populations, enabling them to express engineered ligand-gated ion channels that are responsive to a proprietary small molecule. This interaction allows for precise, dose-dependent control of neuronal activity, facilitating the treatment of conditions such as neuropathic pain, epilepsy, and movement disorders. Coda's approach utilizes viral vectors to deliver these engineered neurotransmitter receptors directly to targeted neurons, enhancing the efficiency of treatment for severe nervous system disorders compared to traditional therapies.

Anokion SA is a biotechnology company based in Ecublens, Switzerland, specializing in antigen-specific immune tolerance solutions. As a spin-off from the Ecole Polytechnique Fédérale de Lausanne, Anokion develops innovative immunotherapy aimed at reducing the immunogenicity of therapeutic proteins. The company's platform technology can be applied across a wide range of clinical indications, targeting both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis, and type 1 diabetes. By engineering proteins or antigens for precise therapy, Anokion aims to provide effective treatment options that minimize side effects, thereby improving patient outcomes in the management of autoimmune and allergic diseases.

Passage Bio, Inc. is a genetic medicines company based in Philadelphia, Pennsylvania, dedicated to developing transformative therapies for rare monogenic central nervous system (CNS) diseases. Established in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while taking responsibility for the clinical development, regulatory processes, manufacturing, and commercialization of its product candidates. The partnership also involves research and development collaborations that support the advancement of innovative treatments for these rare disorders.

Repare Therapeutics Inc. is a precision oncology company based in Montréal, Canada, that specializes in discovering and developing targeted therapeutics through a synthetic lethality approach. Utilizing its proprietary SNIPRx platform, which integrates genome-wide analysis and CRISPR technology, Repare systematically identifies and advances cancer therapies aimed at genomic instability, particularly in DNA damage repair. The company's lead candidate, RP-3500, is an oral small molecule inhibitor designed for solid tumors with specific genomic alterations related to DNA damage repair. In addition, Repare is developing innovative programs such as a CCNE1-SL inhibitor for tumors with CCNE1 amplification and a Polymerase Theta program targeting BRCA mutations and other genomic changes. Founded in 2016, Repare Therapeutics is focused on addressing the unique vulnerabilities of tumor cells in genetically defined patient populations to enhance cancer treatment outcomes.

Chinook Therapeutics, Inc. is a clinical-stage biotechnology company based in Seattle, Washington, that specializes in the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead program is atrasentan, an investigational endothelin receptor antagonist currently prepared for Phase III trials targeting IgA nephropathy and other primary glomerular diseases. In addition to atrasentan, Chinook is developing BION-1301, an investigational anti-APRIL monoclonal antibody evaluated in a Phase Ib trial for IgA nephropathy, and CHK-336, a preclinical candidate aimed at treating an undisclosed ultra-orphan kidney disease. Chinook Therapeutics is also engaged in research programs addressing other rare and severe chronic kidney conditions, including polycystic kidney disease.

Century Therapeutics, Inc. is a biotechnology company focused on developing innovative cell therapies derived from induced pluripotent stem cells (iPSCs) to treat hematologic and solid malignancies. Founded in 2018 and headquartered in Philadelphia, Pennsylvania, the company utilizes a specialized platform that integrates gene editing and protein engineering to create allogeneic therapies. This platform allows for the generation of master cell banks of modified immune effector cells, specifically engineered to optimize performance and reduce the risk of rejection by the host immune system. By employing advanced technologies such as CRISPR-mediated gene editing and proprietary chimeric antigen receptors, Century Therapeutics aims to address significant unmet medical needs in cancer and other diseases.

Oyster Point Pharma, Inc., established in 2015 and headquartered in Princeton, New Jersey, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for ocular surface diseases. Its lead product candidate, OC-01, is a nasal spray formulated as a highly selective nicotinic acetylcholine receptor (nAChR) agonist, currently in Phase III trials for treating the signs and symptoms of dry eye disease, a chronic condition affecting over 30 million Americans. OC-01's novel mechanism of action stimulates tear production by activating the trigeminal parasympathetic pathway, re-establishing tear film homeostasis.

Passage Bio, Inc. is a genetic medicines company based in Philadelphia, Pennsylvania, dedicated to developing transformative therapies for rare monogenic central nervous system (CNS) diseases. Established in 2017, the company aims to create a portfolio of five AAV-delivered therapeutics targeting conditions such as GM1 Gangliosidosis, Frontotemporal dementia, and Krabbe Disease. Passage Bio collaborates closely with the University of Pennsylvania, leveraging its Gene Therapy Program for preclinical work while taking responsibility for the clinical development, regulatory processes, manufacturing, and commercialization of its product candidates. The partnership also involves research and development collaborations that support the advancement of innovative treatments for these rare disorders.

Akero Therapeutics, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, founded in 2017. The company is dedicated to the development and commercialization of innovative treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH), a liver disease characterized by inflammation and damage that can lead to severe complications such as fibrosis and liver failure. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein currently undergoing Phase IIa clinical trials. This candidate aims to address the underlying mechanisms of NASH by reducing liver fat and suppressing inflammation and fibrosis. With a focus on providing effective treatment options for conditions lacking approved therapies, Akero Therapeutics seeks to restore metabolic balance and improve patient outcomes in metabolic disease management.

Aprea Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, that specializes in developing cancer therapeutics aimed at reactivating the mutant p53 tumor suppressor protein. Its primary product candidate, APR-246, is a small molecule p53 reactivator currently undergoing late-stage clinical development for hematologic malignancies, particularly myelodysplastic syndromes and acute myeloid leukemia. Founded in 2006, Aprea is focused on advancing innovative treatments that target critical mechanisms in cancer biology to improve patient outcomes.

Gotham Therapeutics Corp. is a biotechnology company based in New York, founded in 2017, that focuses on developing innovative treatments for patients with cancers, autoimmune disorders, and neurodegenerative diseases. The company specializes in a novel class of drugs that target the machinery of epitranscriptomics, which involves altering the activity of proteins that modify messenger ribonucleic acid (mRNA). By utilizing small molecules that inhibit the transcription of proteins through modifications to mRNA, Gotham Therapeutics aims to enhance treatment options and improve outcomes for individuals affected by serious health conditions.

Coda Biotherapeutics, Inc. is a biotechnology company focused on developing innovative therapies to modulate neuronal activity through its chemogenetic platform. Established in 2014 and based in San Francisco, the company employs gene therapy techniques to modify specific neuronal populations, enabling them to express engineered ligand-gated ion channels that are responsive to a proprietary small molecule. This interaction allows for precise, dose-dependent control of neuronal activity, facilitating the treatment of conditions such as neuropathic pain, epilepsy, and movement disorders. Coda's approach utilizes viral vectors to deliver these engineered neurotransmitter receptors directly to targeted neurons, enhancing the efficiency of treatment for severe nervous system disorders compared to traditional therapies.

Akero Therapeutics, Inc. is a clinical-stage biotechnology company based in South San Francisco, California, founded in 2017. The company is dedicated to the development and commercialization of innovative treatments for serious metabolic diseases, particularly nonalcoholic steatohepatitis (NASH), a liver disease characterized by inflammation and damage that can lead to severe complications such as fibrosis and liver failure. Akero's lead product candidate, AKR-001, is a long-acting Fc fusion modified FGF21 protein currently undergoing Phase IIa clinical trials. This candidate aims to address the underlying mechanisms of NASH by reducing liver fat and suppressing inflammation and fibrosis. With a focus on providing effective treatment options for conditions lacking approved therapies, Akero Therapeutics seeks to restore metabolic balance and improve patient outcomes in metabolic disease management.

Lava Therapeutics B.V. is a biotechnology company based in Utrecht, the Netherlands, focused on innovative cancer treatments. Founded in 2016, it specializes in the development of proprietary bispecific antibodies that engage gamma-delta T cells, aiming to harness the immune system's power to target and destroy tumor cells. The company's platform creates next-generation γδ T cell engaging antibodies designed for both hematological and solid tumors, emphasizing safety, potency, and cost-effectiveness in its biopharmaceuticals. By combining immune recruiting and activating functionalities, Lava Therapeutics seeks to transform cancer therapy and improve patient outcomes.

Enterprise Therapeutics Ltd. is a drug discovery company based in Brighton, United Kingdom, established in 2014. The company is dedicated to researching and developing innovative therapies for respiratory diseases, particularly chronic obstructive pulmonary disease (COPD), cystic fibrosis, and asthma. Its focus is on creating disease-modifying treatments that address the underlying mechanisms of mucus congestion in the lungs, which can lead to breathing difficulties and increase the risk of lung infections. By targeting these mechanisms, Enterprise Therapeutics aims to improve the quality of life for patients suffering from these debilitating conditions.

Tempest Therapeutics Inc. is a biotechnology company based in South San Francisco, California, focused on developing small molecule therapeutics for cancer treatment. Established in 2011, the company aims to enhance anti-tumor immunity through its innovative drug pipeline, which includes clinical-stage candidates such as TPST-8844, TPST-1120, and TPST-1495. TPST-8844 targets an enzyme that helps tumor cells evade immune responses, while TPST-1120 blocks the PPAR-alpha pathway to stimulate immune effector cells essential for fighting tumors. Additionally, the company's therapeutics address pathways that directly kill tumor cells and activate tumor-specific immunity, positioning Tempest Therapeutics at the forefront of cancer treatment innovation.

Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company headquartered in San Diego, California, dedicated to the discovery, development, and commercialization of innovative therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate, paltusotine, is an oral selective nonpeptide somatostatin receptor type 2 biased agonist currently undergoing Phase I clinical trials aimed at treating acromegaly and neuroendocrine tumors. In addition to paltusotine, Crinetics is developing several other therapeutics, including CRN01941, an oral selective nonpeptide sst2 biased agonist for neuroendocrine tumors, and an oral somatostatin type 5 receptor agonist for congenital hyperinsulinism. The company is also working on an oral adrenocorticotrophic hormone antagonist for conditions such as Cushing’s syndrome and congenital adrenal hyperplasia. Founded in 2008, Crinetics Pharmaceuticals is focused on leveraging its internal discovery efforts to create effective treatments while utilizing hormonal biomarker endpoints to enhance the efficiency and cost-effectiveness of its clinical studies.

Quentis Therapeutics, Inc. is a biotechnology company founded in 2016 and based in New York, specializing in the development of cancer immunotherapies. The company's innovative therapeutics focus on modulating endoplasmic reticulum (ER) stress response pathways within the tumor microenvironment. By targeting these pathways, Quentis Therapeutics aims to enhance the immune system's ability to combat cancer, thereby providing patients with access to novel treatment options. The company's approach seeks to translate cutting-edge biological insights into effective therapeutic strategies that can improve anti-tumor immunity.

Pandion Therapeutics, Inc. is a clinical-stage biopharmaceutical company based in Watertown, Massachusetts, focused on developing innovative therapeutics for patients with autoimmune diseases. The company’s lead product candidate, PT101, is an engineered interleukin-2 variant currently undergoing Phase 1a clinical trials for various autoimmune and inflammatory conditions, including moderate-to-severe ulcerative colitis and systemic lupus erythematosus. In addition to PT101, Pandion's pipeline includes PT627, a systemic PD-1 agonist in preclinical studies, and two bifunctional molecules, PT001 and PT002, designed to provide tissue-selective immunomodulation by targeting specific adhesion molecules in the gastrointestinal tract. Pandion employs a network-based approach to immune system conceptualization through its TALON drug design platform and collaborates with Astellas Pharma to develop locally acting immunomodulators for pancreatic autoimmune diseases. The company aims to create a new generation of therapeutics that offer enhanced efficacy and safety for the treatment of autoimmune and inflammatory diseases.

Metavention, Inc., founded in 2012 and based in Dover, Delaware, specializes in developing innovative treatments aimed at permanently disrupting the overactive nerves that contribute to high blood pressure and various metabolic diseases. The company has created a renal denervation procedure that employs radio frequency energy to target and modulate overactive sympathetic nerves. This trans-catheter device not only addresses issues related to high blood pressure but also focuses on conditions such as Type 2 diabetes by employing standard interventional vascular techniques. By providing physicians with advanced tools for diagnosis and treatment, Metavention aims to enhance patient outcomes for those suffering from metabolic disorders linked to sympathetic nervous system activity.

Aligos Therapeutics, Inc. is a clinical-stage biopharmaceutical company founded in 2018 and based in South San Francisco, California. The company is dedicated to developing innovative therapeutics to meet unmet medical needs in viral and liver diseases. Its primary focus is on chronic hepatitis B (CHB), with a robust pipeline that includes several drug candidates: ALG-010133, a synthetic oligonucleotide currently in Phase I clinical trials; ALG-000184, a capsid assembly modulator; ALG-020572, another oligonucleotide; and ALG-125097, an siRNA drug candidate. Additionally, Aligos is advancing ALG-055009, a small molecule THR-ß agonist aimed at treating non-alcoholic steatohepatitis (NASH). Aligos aims to leverage its expertise in liver diseases and viral infections to develop targeted antiviral therapies and establish itself as a leader in this therapeutic area.

Jnana Therapeutics Inc. is a biotechnology company based in Boston, Massachusetts, founded in 2016. It specializes in drug discovery, particularly focusing on solute carrier (SLC) transporters, which are vital for understanding various disease pathways. The company’s efforts are directed towards immunometabolism, lysosomal function, and mucosal defense, with applications in immuno-oncology, inflammatory disorders, and neurological diseases. Utilizing its proprietary RAPID platform, Jnana accelerates the identification of therapeutic targets and the development of small molecule therapies. By leveraging advanced chemoproteomics techniques, the company aims to enhance the efficiency of drug discovery and address significant unmet medical needs in patient care.

Oyster Point Pharma, Inc., established in 2015 and headquartered in Princeton, New Jersey, is a clinical-stage biopharmaceutical company dedicated to developing and commercializing innovative therapies for ocular surface diseases. Its lead product candidate, OC-01, is a nasal spray formulated as a highly selective nicotinic acetylcholine receptor (nAChR) agonist, currently in Phase III trials for treating the signs and symptoms of dry eye disease, a chronic condition affecting over 30 million Americans. OC-01's novel mechanism of action stimulates tear production by activating the trigeminal parasympathetic pathway, re-establishing tear film homeostasis.

Gritstone bio is a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surface of infected cells. Gritstone bio's approach leverages the body's natural immune system recognition of targets on abnormal cells, which is applicable to both anti-tumor and anti-viral immunity. Their pipeline includes several product candidates for treating solid tumors, such as GRANITE, SLATE, and CORAL. The company operates in a field that has seen significant advancements with the development and commercialization of immunotherapy drugs like checkpoint inhibitors, transforming cancer treatment.

Repare Therapeutics Inc. is a precision oncology company based in Montréal, Canada, that specializes in discovering and developing targeted therapeutics through a synthetic lethality approach. Utilizing its proprietary SNIPRx platform, which integrates genome-wide analysis and CRISPR technology, Repare systematically identifies and advances cancer therapies aimed at genomic instability, particularly in DNA damage repair. The company's lead candidate, RP-3500, is an oral small molecule inhibitor designed for solid tumors with specific genomic alterations related to DNA damage repair. In addition, Repare is developing innovative programs such as a CCNE1-SL inhibitor for tumors with CCNE1 amplification and a Polymerase Theta program targeting BRCA mutations and other genomic changes. Founded in 2016, Repare Therapeutics is focused on addressing the unique vulnerabilities of tumor cells in genetically defined patient populations to enhance cancer treatment outcomes.

Tarveda Therapeutics, Inc. is a biotechnology company focused on developing innovative cancer therapies aimed at addressing the complexities of treating solid tumors. Founded in 2011 and based in Watertown, Massachusetts, the company specializes in miniature drug conjugates. Its lead candidate, PEN-866, utilizes a platform that targets the activated form of Heat Shock Protein 90 (HSP90) in tumors, delivering a potent topoisomerase 1 inhibitor payload, SN38. Additionally, Tarveda is evaluating another miniature drug conjugate designed for patients with somatostatin receptor 2 (SSTR2) expressing neuroendocrine tumors, small cell lung cancer, and other solid tumors. Through its targeted approach, Tarveda seeks to extend the lives of patients facing challenging cancers while minimizing potential toxicities associated with treatment.

Veran Medical Technologies, Inc. is a medical device company specializing in minimally invasive therapeutic devices for interventional oncology. Headquartered in St. Louis, Missouri, the company focuses on developing products that assist physicians in diagnosing diseases and delivering targeted therapies. Its offerings include the SPiNView thoracic navigation system, an electromagnetic device designed for the biopsy of solitary pulmonary nodules, and the ig4 IR System, which aids in performing biopsies and other procedures for the lungs, liver, and kidneys. Additionally, Veran Medical provides various instruments such as the vPad2 tracker device and the SPiNPerc hybrid diagnostic tool. The company's innovative solutions utilize advanced imaging technologies to create dynamic 3D maps of respiratory pathways, enhancing procedural planning and navigation, ultimately helping clinicians to expedite cancer diagnosis and treatment. Founded in 2003, Veran Medical Technologies is committed to improving patient outcomes through precision-guided interventions.

Turnstone Biologics Inc. is a clinical-stage biotechnology company based in Ottawa, Canada, with an additional office in New York. Founded in 2015, the company is dedicated to advancing innovative viral immunotherapies aimed at improving cancer patient survival. Its lead product, RIVAL-01, utilizes a vaccinia virus backbone that encodes several immunomodulators, including Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine, which work together to enhance immune activity and optimize the tumor microenvironment for effective cancer treatment. Additionally, Turnstone Biologics is developing next-generation tumor-infiltrating lymphocyte (TIL) therapies by isolating and expanding the most potent and tumor-reactive T cells from patients' tumors, thereby harnessing the body's own immune system to combat solid tumors. Through these innovative approaches, Turnstone Biologics aims to deliver breakthrough cancer immunotherapies that significantly improve clinical outcomes for patients.

Aprea Therapeutics, Inc. is a biopharmaceutical company based in Boston, Massachusetts, that specializes in developing cancer therapeutics aimed at reactivating the mutant p53 tumor suppressor protein. Its primary product candidate, APR-246, is a small molecule p53 reactivator currently undergoing late-stage clinical development for hematologic malignancies, particularly myelodysplastic syndromes and acute myeloid leukemia. Founded in 2006, Aprea is focused on advancing innovative treatments that target critical mechanisms in cancer biology to improve patient outcomes.

Crinetics Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company headquartered in San Diego, California, dedicated to the discovery, development, and commercialization of innovative therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate, paltusotine, is an oral selective nonpeptide somatostatin receptor type 2 biased agonist currently undergoing Phase I clinical trials aimed at treating acromegaly and neuroendocrine tumors. In addition to paltusotine, Crinetics is developing several other therapeutics, including CRN01941, an oral selective nonpeptide sst2 biased agonist for neuroendocrine tumors, and an oral somatostatin type 5 receptor agonist for congenital hyperinsulinism. The company is also working on an oral adrenocorticotrophic hormone antagonist for conditions such as Cushing’s syndrome and congenital adrenal hyperplasia. Founded in 2008, Crinetics Pharmaceuticals is focused on leveraging its internal discovery efforts to create effective treatments while utilizing hormonal biomarker endpoints to enhance the efficiency and cost-effectiveness of its clinical studies.

Turnstone Biologics Inc. is a clinical-stage biotechnology company based in Ottawa, Canada, with an additional office in New York. Founded in 2015, the company is dedicated to advancing innovative viral immunotherapies aimed at improving cancer patient survival. Its lead product, RIVAL-01, utilizes a vaccinia virus backbone that encodes several immunomodulators, including Flt3 ligand, anti-CTLA-4 antibody, and IL-12 cytokine, which work together to enhance immune activity and optimize the tumor microenvironment for effective cancer treatment. Additionally, Turnstone Biologics is developing next-generation tumor-infiltrating lymphocyte (TIL) therapies by isolating and expanding the most potent and tumor-reactive T cells from patients' tumors, thereby harnessing the body's own immune system to combat solid tumors. Through these innovative approaches, Turnstone Biologics aims to deliver breakthrough cancer immunotherapies that significantly improve clinical outcomes for patients.

Gritstone bio is a biotechnology company focused on developing immunotherapies for cancer and infectious diseases. The company initially concentrated on tumor-specific neoantigens but has expanded its programs to include viral antigens found on the surface of infected cells. Gritstone bio's approach leverages the body's natural immune system recognition of targets on abnormal cells, which is applicable to both anti-tumor and anti-viral immunity. Their pipeline includes several product candidates for treating solid tumors, such as GRANITE, SLATE, and CORAL. The company operates in a field that has seen significant advancements with the development and commercialization of immunotherapy drugs like checkpoint inhibitors, transforming cancer treatment.

Audentes Therapeutics, a clinical stage biotechnology company based in San Francisco, specializes in developing gene therapy products aimed at treating serious, life-threatening rare diseases resulting from single gene defects. The company is advancing several therapeutic candidates, including AT132 for X-linked myotubular myopathy, AT342 for Crigler-Najjar syndrome, and AT845, which is in preclinical studies for Pompe disease. Additionally, Audentes is developing vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. It has established collaborative agreements with Genethon and the University of Pennsylvania to further research and commercialization efforts for these therapies. Founded in 2012, Audentes Therapeutics was acquired by Astellas Pharma in January 2020 and operates under the name Astellas Gene Therapies, focusing on gene therapy research, development, and future commercialization.

Veran Medical Technologies, Inc. is a medical device company specializing in minimally invasive therapeutic devices for interventional oncology. Headquartered in St. Louis, Missouri, the company focuses on developing products that assist physicians in diagnosing diseases and delivering targeted therapies. Its offerings include the SPiNView thoracic navigation system, an electromagnetic device designed for the biopsy of solitary pulmonary nodules, and the ig4 IR System, which aids in performing biopsies and other procedures for the lungs, liver, and kidneys. Additionally, Veran Medical provides various instruments such as the vPad2 tracker device and the SPiNPerc hybrid diagnostic tool. The company's innovative solutions utilize advanced imaging technologies to create dynamic 3D maps of respiratory pathways, enhancing procedural planning and navigation, ultimately helping clinicians to expedite cancer diagnosis and treatment. Founded in 2003, Veran Medical Technologies is committed to improving patient outcomes through precision-guided interventions.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.

PIQUR Therapeutics AG is a clinical-stage pharmaceutical company based in Basel, Switzerland, founded in 2011. The company specializes in the discovery and development of innovative anti-cancer drugs, focusing on lipid kinase (PI3K) and mTOR inhibition, which are recognized as effective drug targets in oncology. PIQUR's pipeline includes promising compounds, with its lead drug, bimiralisib, designed to dual inhibit the PI3K/mTOR pathway. By developing targeted therapies for oncology and dermatology, PIQUR Therapeutics aims to improve the lives of cancer patients and address genetic diseases, ultimately enhancing their recovery and overall quality of life. The company holds a secured patent scope that protects many of its chemical compounds, reinforcing its commitment to advancing cancer treatment.

CRISPR Therapeutics AG is a biotechnology company based in Zug, Switzerland, dedicated to developing transformative gene-based medicines for serious human diseases using CRISPR/Cas9 technology. This revolutionary gene-editing platform allows for precise changes to genomic DNA. The company's portfolio includes therapeutic programs targeting hemoglobinopathies, oncology, regenerative medicine, and rare diseases. Their lead product candidate is CTX001, a gene-edited therapy for transfusion-dependent beta thalassemia or severe sickle cell disease, which has been approved as Casgevy in collaboration with Vertex Pharmaceuticals. Additionally, CRISPR Therapeutics is developing CTX110, an allogeneic CAR-T therapy targeting CD19-positive malignancies, and other programs like CTX120 for multiple myeloma and CTX130 for solid tumors and hematologic malignancies. The company also engages in regenerative medicine programs for diabetes and genetic disease treatments such as glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. CRISPR Therapeutics has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc.

CRISPR Therapeutics AG is a biotechnology company based in Zug, Switzerland, dedicated to developing transformative gene-based medicines for serious human diseases using CRISPR/Cas9 technology. This revolutionary gene-editing platform allows for precise changes to genomic DNA. The company's portfolio includes therapeutic programs targeting hemoglobinopathies, oncology, regenerative medicine, and rare diseases. Their lead product candidate is CTX001, a gene-edited therapy for transfusion-dependent beta thalassemia or severe sickle cell disease, which has been approved as Casgevy in collaboration with Vertex Pharmaceuticals. Additionally, CRISPR Therapeutics is developing CTX110, an allogeneic CAR-T therapy targeting CD19-positive malignancies, and other programs like CTX120 for multiple myeloma and CTX130 for solid tumors and hematologic malignancies. The company also engages in regenerative medicine programs for diabetes and genetic disease treatments such as glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. CRISPR Therapeutics has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc.

Laguna Pharmaceuticals Inc. is a biopharmaceutical company focused on the development and marketing of small molecule pharmaceuticals, specifically targeting the treatment of atrial fibrillation (AF) and atrial flutter (AFL). The company, originally established as ChanRx Corp. in 2006, rebranded to its current name in February 2015. With its headquarters in La Jolla, California, Laguna Pharmaceuticals is dedicated to advancing therapeutic options for patients suffering from these common cardiac conditions, which can lead to serious health complications such as heart attacks and strokes.

Audentes Therapeutics, a clinical stage biotechnology company based in San Francisco, specializes in developing gene therapy products aimed at treating serious, life-threatening rare diseases resulting from single gene defects. The company is advancing several therapeutic candidates, including AT132 for X-linked myotubular myopathy, AT342 for Crigler-Najjar syndrome, and AT845, which is in preclinical studies for Pompe disease. Additionally, Audentes is developing vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. It has established collaborative agreements with Genethon and the University of Pennsylvania to further research and commercialization efforts for these therapies. Founded in 2012, Audentes Therapeutics was acquired by Astellas Pharma in January 2020 and operates under the name Astellas Gene Therapies, focusing on gene therapy research, development, and future commercialization.

Ivantis Inc. is a medical device company based in Irvine, California, focused on developing innovative treatments for primary open-angle glaucoma. Founded in 2007, the company has created a minimally invasive intracanalicular scaffold that helps alleviate high intraocular pressure by restoring the natural drainage pathway in Schlemm's canal. This device aims to provide a less invasive and more effective solution for the over 60 million individuals worldwide affected by this condition. In addition to its glaucoma treatments, Ivantis plans to expand its research and development efforts to address other challenging diseases within the field of ophthalmology. The company's products are utilized in clinical trials by ophthalmology specialists across the United States.

Anokion SA is a biotechnology company based in Ecublens, Switzerland, specializing in antigen-specific immune tolerance solutions. As a spin-off from the Ecole Polytechnique Fédérale de Lausanne, Anokion develops innovative immunotherapy aimed at reducing the immunogenicity of therapeutic proteins. The company's platform technology can be applied across a wide range of clinical indications, targeting both prevalent and rare autoimmune diseases, including celiac disease, multiple sclerosis, and type 1 diabetes. By engineering proteins or antigens for precise therapy, Anokion aims to provide effective treatment options that minimize side effects, thereby improving patient outcomes in the management of autoimmune and allergic diseases.

CRISPR Therapeutics AG is a biotechnology company based in Zug, Switzerland, dedicated to developing transformative gene-based medicines for serious human diseases using CRISPR/Cas9 technology. This revolutionary gene-editing platform allows for precise changes to genomic DNA. The company's portfolio includes therapeutic programs targeting hemoglobinopathies, oncology, regenerative medicine, and rare diseases. Their lead product candidate is CTX001, a gene-edited therapy for transfusion-dependent beta thalassemia or severe sickle cell disease, which has been approved as Casgevy in collaboration with Vertex Pharmaceuticals. Additionally, CRISPR Therapeutics is developing CTX110, an allogeneic CAR-T therapy targeting CD19-positive malignancies, and other programs like CTX120 for multiple myeloma and CTX130 for solid tumors and hematologic malignancies. The company also engages in regenerative medicine programs for diabetes and genetic disease treatments such as glycogen storage disease Ia, Duchenne muscular dystrophy, and cystic fibrosis. CRISPR Therapeutics has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, and ViaCyte, Inc.

ForSight VISION5, founded in 2010 as part of ForSight Labs, specializes in the development of non-invasive drug delivery technologies aimed at treating major eye diseases such as glaucoma, dry eye, and allergies. The company is focused on creating innovative products that can replace traditional eye drops and offer sustained therapeutic effects. Currently, ForSight VISION5 is advancing its lead product, the Helios insert, which is undergoing its second Phase 2 clinical study, reflecting the company's commitment to improving patient care in ophthalmology through effective and patient-friendly solutions.

AAVLife is a gene therapy company established in 2014 and headquartered in Paris, France. The firm focuses on developing treatments for Friedreich’s Ataxia Cardiomyopathy, a serious genetic disorder that leads to progressive neurological and cardiac symptoms, often manifesting in childhood or adolescence. AAVLife's innovative research utilizes adeno-associated virus (AAV) technology to deliver a normal gene to cardiac tissue, which has shown promise in reversing heart dysfunction in preclinical mouse models. The company's efforts have included planning clinical trials and collaborating with regulatory authorities to address safety and design aspects of the studies. AAVLife aims to advance its gene therapy approach to improve cardiac health in individuals affected by this life-threatening condition, emphasizing its commitment to patient communities and the organizations that support them.

PIQUR Therapeutics AG is a clinical-stage pharmaceutical company based in Basel, Switzerland, founded in 2011. The company specializes in the discovery and development of innovative anti-cancer drugs, focusing on lipid kinase (PI3K) and mTOR inhibition, which are recognized as effective drug targets in oncology. PIQUR's pipeline includes promising compounds, with its lead drug, bimiralisib, designed to dual inhibit the PI3K/mTOR pathway. By developing targeted therapies for oncology and dermatology, PIQUR Therapeutics aims to improve the lives of cancer patients and address genetic diseases, ultimately enhancing their recovery and overall quality of life. The company holds a secured patent scope that protects many of its chemical compounds, reinforcing its commitment to advancing cancer treatment.

Bird Rock Bio, Inc. is a clinical-stage biopharmaceutical company based in La Jolla, California, with a research facility in Shanghai, China. The company specializes in the discovery and development of novel biologic therapeutics aimed at addressing immune-inflammatory conditions, including rheumatoid arthritis, metabolic diseases, fibrosis, and nonalcoholic steatohepatitis. Bird Rock Bio's technology focuses on creating highly selective monoclonal antibodies targeting specific members of the G-protein coupled receptor (GPCR) family, a class of proteins critical for therapeutic efficacy. Its lead product, RYI-008, is a potent monoclonal antibody targeting IL-6, a cytokine linked to inflammation and cancer. The company is dedicated to meeting the medical needs of patients in China while also aiming for global impact. Bird Rock Bio has a growing pipeline of therapeutic antibodies developed through proprietary technologies that ensure specificity and effectiveness in treatment.

Immune Design Corp., a clinical-stage immunotherapy company based in Seattle, Washington, focuses on enabling the body's immune system to combat diseases, with a primary emphasis on cancer treatment. The company leverages its ZVex and GLAAS discovery platforms to develop innovative therapies. Its lead product candidate is G100, currently in Phase II clinical trials for treating follicular non-Hodgkin lymphoma, both as a monotherapy and in combination therapy. Immune Design has collaboration and license agreements with Sanofi Pasteur. The company was founded in 2008 and operates under the umbrella of Merck & Co., Inc.

Audentes Therapeutics, a clinical stage biotechnology company based in San Francisco, specializes in developing gene therapy products aimed at treating serious, life-threatening rare diseases resulting from single gene defects. The company is advancing several therapeutic candidates, including AT132 for X-linked myotubular myopathy, AT342 for Crigler-Najjar syndrome, and AT845, which is in preclinical studies for Pompe disease. Additionally, Audentes is developing vectorized antisense treatments for Duchenne muscular dystrophy and myotonic dystrophy type 1. It has established collaborative agreements with Genethon and the University of Pennsylvania to further research and commercialization efforts for these therapies. Founded in 2012, Audentes Therapeutics was acquired by Astellas Pharma in January 2020 and operates under the name Astellas Gene Therapies, focusing on gene therapy research, development, and future commercialization.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on the discovery and development of gene therapies for retinal degenerative diseases and neurodegenerative disorders of the central nervous system. Founded in 2012, the company utilizes innovative technologies, including mitochondrial targeting sequences and optogenetics, to develop treatments that aim to preserve or restore vision in patients with severe vision impairments. Its lead product candidates include GS010, an AAV2-based gene therapy that is currently undergoing Phase III clinical trials for Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is in Phase I/II trials for retinitis pigmentosa and geographic atrophy associated with dry age-related macular degeneration. GenSight Biologics is also advancing other product candidates in preclinical development targeting various ophthalmic and neurodegenerative conditions.